DiaMedica Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Net Loss Per Share (Tables)

Note 11 - Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2022

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		Three Months Ended June 30,								Six Months Ended June 30,
		2022				2021				2022				2021
Net loss		$	(3,358	)		$	(3,274	)		$	(6,866	)		$	(6,896	)
Weighted average shares outstanding—basic and diluted			26,443,067				18,786,157				26,443,067				18,776,461
Basic and diluted net loss per share		$	(0.13	)		$	(0.17	)		$	(0.26	)		$	(0.37	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

		Three Months Ended June 30,								Six Months Ended June 30,
		2022				2021				2022				2021
Employee and non-employee stock options			2,623,998				1,421,092				2,623,998				1,421,092
Common shares issuable under common share purchase warrants			265,000				265,000				265,000				265,000
Common shares issuable under deferred stock units			134,402				72,142				134,402				72,142